Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders ...

Biogen and Neomorph have entered a research partnership aimed at discovering and developing molecular glue degraders for the ...

Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph that could be worth up ...

About three months before that, Novo Nordisk in February linked up with California’s Neomorph in its own $1.46 billion accord to discover, develop and commercialize glue degraders against a ...

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...

Two days after Monte Rosa Therapeutics Inc. signed a molecular glue degrader deal with Novartis AG, two other companies, Biogen Inc. and Neomorph Inc., are moving forward in the same space in a ...

As part of the collaboration, the companies aim to utilize Neomorph’s proprietary molecular glue discovery platform to accelerate the identification and validation of novel small molecule ...